Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers and male malignancies. Despite recognised clinico-pathological and molecular differences to female breast cancer (FBC), the clinical management of MBC follows established FBC treatment strategies. Loss of function mutations in the DNA damage response genes BRCA1 and BRCA2, have been strongly implicated in the pathogenesis of MBC. While there have been extensive clinical advancements in other BRCA-related malignancies, including FBC, improvements in MBC remain stagnant. Here we present a review that highlights the lack of treatment evidence for BRCA-related MBC and the required national and global collaborative effort to address this unmet need. In doing so, we summarise the transformative clinical advancements with poly(ADP-ribose) polymerase (PARP) inhibitors in other BRCA-related cancers namely, FBC and prostate cancer.
Objective: Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in the UK. Early identification and timely intervention rely heavily on the faecal immunohistochemical test (FIT). However, FIT diagnostic accuracy varies, with a sensitivity ranging between 85% and 94% and a noteworthy negative predictive value (NPV) of 99%. The objective of this study was to evaluate the diagnostic accuracy of FIT in detecting CRC and advanced adenomas in patients referred through the 2-week wait (2WW) referral pathway following the National Institute for Health and Care Excellence (NICE) NG12 criteria. Method: A retrospective analysis was conducted on 1841 patients who were referred through the 2WW pathway. Data on clinical characteristics, FIT test positivity (faecal haemoglobin ≥ 10 µg/g), and subsequent investigations were obtained. The sensitivity, specificity, positive predictive value (PPV), and NPV were calculated based on the presence of adenomas (≥10 mm) or malignancies. Results: Positive FIT results were observed in 73.4%, negative FIT in 25.9%, and 0.65% of patients lacked FIT availability. The sensitivity, specificity, PPV, and NPV for CRC detection compared to the presence of advanced adenoma or CRC were 96.49% vs. 93.6%, 26.56% vs. 30.2%, 7.31% vs. 21.8%, and 99.18% vs. 95.8%, respectively. Conclusion: FIT showed the expected performance for CRC detection with an NPV of 99.18%, but a negative FIT result should not exclude investigation with colonoscopy due to a 4.2% likelihood of missing advanced adenomas. There is still a need for other types of testing for CRC screening.